Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liora Schultz

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Plos One|July 11, 2019
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosminRupa Narayan, Niclas Olsson, Lisa E Wagar, et al.
Frontiers in Immunology|October 10, 2024
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapyClaire Johns, Courtney Erickson, Ashley Jacobs, et al.
Frontiers in Oncology|December 16, 2022
Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patientsAgnes Reschke, Rebecca M Richards, Stephanie M Smith, et al.
Hemasphere|December 10, 2025
Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statementAdam Lamble, Sandra D Bohling, Kara L Davis, et al.
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Nature Reviews. Clinical Oncology|January 23, 2026
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancerLiora Schultz, Kevin McNerney, Adam J Lamble, et al.
Blood|January 29, 2021
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphomaJohn H Baird, Matthew J Frank, Juliana Craig, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Plos One|July 11, 2019
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosminRupa Narayan, Niclas Olsson, Lisa E Wagar, et al.
Frontiers in Immunology|October 10, 2024
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapyClaire Johns, Courtney Erickson, Ashley Jacobs, et al.
Frontiers in Oncology|December 16, 2022
Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patientsAgnes Reschke, Rebecca M Richards, Stephanie M Smith, et al.
Hemasphere|December 10, 2025
Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statementAdam Lamble, Sandra D Bohling, Kara L Davis, et al.
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Nature Reviews. Clinical Oncology|January 23, 2026
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancerLiora Schultz, Kevin McNerney, Adam J Lamble, et al.
Blood|January 29, 2021
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphomaJohn H Baird, Matthew J Frank, Juliana Craig, et al.
Nature Medicine|July 27, 2021
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y Spiegel, Shabnum Patel, Lori Muffly, et al.
Pageof 2